FOXP3: Genetic and epigenetic implications for autoimmunity

Journal of Autoimmunity

Volumn 41, Issue , 2013, Pages 72-78

  Katoh, Hiroto ^a   Zheng, Pan ^b   Liu, Yang ^c  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF MICHIGAN   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Autoimmune diseases; Epigenetics; FOXP3

Indexed keywords

ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; TRANSCRIPTION FACTOR FOXP3; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNITY; COLITIS; EPIGENETICS; EXPERIMENTAL THERAPY; GENE MUTATION; HUMAN; IPEX SYNDROME; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNITY; EPIGENESIS, GENETIC; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GENETIC DISEASES, X-LINKED; HISTONE DEACETYLASES; HUMANS; INTESTINAL DISEASES; MUTATION; POLYENDOCRINOPATHIES, AUTOIMMUNE; SYNDROME;

EID: 84875936395     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.12.004     Document Type: Review

References (91)

1. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
2. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
3. Chatila T.A., Blaeser F., Ho N., Lederman H.M., Voulgaropoulos C., Helms C., et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. The Journal of clinical investigation 2000, 106:R75-R81.
4. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
5. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001, 27:18-20.
6. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
7. Zuo T., Wang L., Morrison C., Chang X., Zhang H., Li W., et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007, 129:1275-1286.
8. Wang L., Liu R., Li W., Chen C., Katoh H., Chen G.Y., et al. Somatic Single Hits Inactivate the X-Linked Tumor Suppressor FOXP3 in the Prostate. Cancer Cell 2009, 16:336-346.
9. Zhang H.Y., Sun H. Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Lett 2010, 287:91-97.
10. Hinz S., Pagerols-Raluy L., Oberg H.H., Ammerpohl O., Grussel S., Sipos B., et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Research 2007, 67:8344-8350.
11. Cunha L.L., Morari E.C., Nonogaki S., Soares F.A., Vassallo J., Ward L.S. Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics (Sao Paulo) 2012, 67:483-488.
12. Yoshii M., Tanaka H., Ohira M., Muguruma K., Iwauchi T., Lee T., et al. Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach. Br J Cancer 2012, 106:1668-1674.
13. Ebert L.M., Tan B.S., Browning J., Svobodova S., Russell S.E., Kirkpatrick N., et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 2008, 68:3001-3009.
14. Krejsgaard T., Gjerdrum L.M., Ralfkiaer E., Lauenborg B., Eriksen K.W., Mathiesen A.M., et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome. Leukemia 2008, 22:2230-2239.
15. Zuo T., Liu R., Zhang H., Chang X., Liu Y., Wang L., et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. The Journal of clinical investigation 2007, 117:3765-3773.
16. Liu R., Wang L., Chen G., Katoh H., Chen C., Liu Y., et al. FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. Cancer research 2009, 69:2252-2259.
17. Li W., Wang L., Katoh H., Liu R., Zheng P., Liu Y. Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers. Cancer Res 2011, 71:2162-2171.
18. Katoh H., Zheng P., Liu Y. Signalling through FOXP3 as an X-linked Tumor Suppressor. Int J Biochem Cell Biol 2010, 42:1784-1787.
19. Liu Y., Wang L., Zheng P. X-linked tumor suppressors: perplexing inheritance, a unique therapeutic opportunity. Trends Genet 2010, 26:260-265.
20. Katoh H., Qin Z.S., Liu R., Wang L., Li W., Li X., et al. FOXP3 orchestrates H4K16 acetylation and H3K4 trimethylation for activation of multiple genes by recruiting MOF and causing displacement of PLU-1. Mol Cell 2011, 44:770-784.
21. An Y.F., Xu F., Wang M., Zhang Z.Y., Zhao X.D. Clinical and molecular characteristics of immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome in China. Scandinavian journal of immunology 2011, 74:304-309.
22. Bacchetta R., Passerini L., Gambineri E., Dai M., Allan S.E., Perroni L., et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. The Journal of clinical investigation 2006, 116:1713-1722.
23. Baud O., Goulet O., Canioni D., Le Deist F., Radford I., Rieu D., et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. The New England journal of medicine 2001, 344:1758-1762.
24. Burroughs L.M., Storb R., Leisenring W.M., Pulsipher M.A., Loken M.R., Torgerson T.R., et al. Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone marrow transplantation 2007, 40:633-642.
25. De Benedetti F., Insalaco A., Diamanti A., Cortis E., Muratori F., Lamioni A., et al. Mechanistic associations of a mild phenotype of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome. Clin Gastroenterol Hepatol 2006, 4:653-659.
26. d'Hennezel E., Ben-Shoshan M., Ochs H.D., Torgerson T.R., Russell L.J., Lejtenyi C., et al. FOXP3 forkhead domain mutation and regulatory T cells in the IPEX syndrome. The New England journal of medicine 2009, 361:1710-1713.
27. Ferguson P.J., Blanton S.H., Saulsbury F.T., McDuffie M.J., Lemahieu V., Gastier J.M., et al. Manifestations and linkage analysis in X-linked autoimmunity-immunodeficiency syndrome. American journal of medical genetics 2000, 90:390-397.
28. Fuchizawa T., Adachi Y., Ito Y., Higashiyama H., Kanegane H., Futatani T., et al. Developmental changes of FOXP3-expressing CD4+CD25+ regulatory T cells and their impairment in patients with FOXP3 gene mutations. Clinical immunology (Orlando, Fla) 2007, 125:237-246.
29. Gambineri E., Perroni L., Passerini L., Bianchi L., Doglioni C., Meschi F., et al. Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol 2008, 122:1105-1112. e1.
30. Gavin M.A., Torgerson T.R., Houston E., DeRoos P., Ho W.Y., Stray-Pedersen A., et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:6659-6664.
31. Halabi-Tawil M., Ruemmele F.M., Fraitag S., Rieux-Laucat F., Neven B., Brousse N., et al. Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. The British journal of dermatology 2009, 160:645-651.
32. Hashimura Y., Nozu K., Kanegane H., Miyawaki T., Hayakawa A., Yoshikawa N., et al. Minimal change nephrotic syndrome associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Pediatric nephrology (Berlin, Germany) 2009, 24:1181-1186.
33. Heltzer M.L., Choi J.K., Ochs H.D., Sullivan K.E., Torgerson T.R., Ernst L.M. A potential screening tool for IPEX syndrome. Pediatr Dev Pathol 2007, 10:98-105.
34. Kasow K.A., Morales-Tirado V.M., Wichlan D., Shurtleff S.A., Abraham A., Persons D.A., et al. Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX. Clinical immunology (Orlando. Fla 2011, 141:169-176.
35. Kobayashi I., Shiari R., Yamada M., Kawamura N., Okano M., Yara A., et al. Novel mutations of FOXP3 in two Japanese patients with immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX). Journal of medical genetics 2001, 38:874-876.
36. Kobayashi I., Kubota M., Yamada M., Tanaka H., Itoh S., Sasahara Y., et al. Autoantibodies to villin occur frequently in IPEX, a severe immune dysregulation, syndrome caused by mutation of FOXP3. Clinical immunology (Orlando, Fla) 2011, 141:83-89.
37. Levy-Lahad E., Wildin R.S. Neonatal diabetes mellitus, enteropathy, thrombocytopenia, and endocrinopathy: Further evidence for an X-linked lethal syndrome. The Journal of pediatrics 2001, 138:577-580.
38. Lopez S.I., Ciocca M., Oleastro M., Cuarterolo M.L., Rocca A., de Davila M.T., et al. Autoimmune hepatitis type 2 in a child with IPEX syndrome. Journal of pediatric gastroenterology and nutrition 2011, 53:690-693.
39. McGinness J.L., Bivens M.M., Greer K.E., Patterson J.W., Saulsbury F.T. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature. Journal of the American Academy of Dermatology 2006, 55:143-148.
40. McMurchy A.N., Gillies J., Allan S.E., Passerini L., Gambineri E., Roncarolo M.G., et al. Point mutants of forkhead box P3 that cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked have diverse abilities to reprogram T cells into regulatory T cells. The Journal of allergy and clinical immunology 2010, 126:1242-1251.
41. Moes N., Rieux-Laucat F., Begue B., Verdier J., Neven B., Patey N., et al. Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy. Gastroenterology 2010, 139:770-778.
42. Moudgil A., Perriello P., Loechelt B., Przygodzki R., Fitzerald W., Kamani N. Immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: an unusual cause of proteinuria in infancy. Pediatric nephrology (Berlin, Germany) 2007, 22:1799-1802.
43. Myers A.K., Perroni L., Costigan C., Reardon W. Clinical and molecular findings in IPEX syndrome. Archives of disease in childhood 2006, 91:63-64.
44. Nieves D.S., Phipps R.P., Pollock S.J., Ochs H.D., Zhu Q., Scott G.A., et al. Dermatologic and immunologic findings in the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Archives of dermatology 2004, 140:466-472.
45. Otsubo K., Kanegane H., Kamachi Y., Kobayashi I., Tsuge I., Imaizumi M., et al. Identification of FOXP3-negative regulatory T-like (CD4(+)CD25(+)CD127(low)) cells in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Clinical immunology (Orlando, Fla) 2011, 141:111-120.
46. Owen C.J., Jennings C.E., Imrie H., Lachaux A., Bridges N.A., Cheetham T.D., et al. Mutational analysis of the FOXP3 gene and evidence for genetic heterogeneity in the immunodysregulation, polyendocrinopathy, enteropathy syndrome. The Journal of clinical endocrinology and metabolism 2003, 88:6034-6039.
47. Passerini L., Olek S., Di Nunzio S., Barzaghi F., Hambleton S., Abinun M., et al. Forkhead box protein 3 (FOXP3) mutations lead to increased TH17 cell numbers and regulatory T-cell instability. J Allergy Clin Immunol 2011, 128:1376-1379. e1.
48. Patey-Mariaud de Serre N., Canioni D., Ganousse S., Rieux-Laucat F., Goulet O., Ruemmele F., et al. Digestive histopathological presentation of IPEX syndrome. Mod Pathol 2009, 22:95-102.
49. Peake J.E., McCrossin R.B., Byrne G., Shepherd R. X-linked immune dysregulation, neonatal insulin dependent diabetes, and intractable diarrhoea. Arch Dis Child Fetal Neonatal Ed 1996, 74:F195-F199.
50. Rao A., Kamani N., Filipovich A., Lee S.M., Davies S.M., Dalal J., et al. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 2007, 109:383-385.
51. Redding A.R., Lew D.B., Conley M.E., Pivnick E.K. An infant with erythroderma, skin scaling, chronic emesis, and intractable diarrhea. Clinical pediatrics 2009, 48:978-980.
52. Rubio-Cabezas O., Minton J.A., Caswell R., Shield J.P., Deiss D., Sumnik Z., et al. Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. Diabetes care 2009, 32:111-116.
53. Scaillon M., Van Biervliet S., Bontems P., Dorchy H., Hanssens L., Ferster A., et al. Severe gastritis in an insulin-dependent child with an IPEX syndrome. Journal of pediatric gastroenterology and nutrition 2009, 49:368-370.
54. Suzuki S., Makita Y., Mukai T., Matsuo K., Ueda O., Fujieda K. Molecular basis of neonatal diabetes in Japanese patients. The Journal of clinical endocrinology and metabolism 2007, 92:3979-3985.
55. Taddio A., Faleschini E., Valencic E., Granzotto M., Tommasini A., Lepore L., et al. Medium-term survival without haematopoietic stem cell transplantation in a case of IPEX: insights into nutritional and immunosuppressive therapy. European journal of pediatrics 2007, 166:1195-1197.
56. Tanaka H., Tsugawa K., Kudo M., Sugimoto K., Kobayashi I., Ito E. Low-dose cyclosporine A in a patient with X-linked immune dysregulation, polyendocrinopathy and enteropathy. European journal of pediatrics 2005, 164:779-780.
57. Tsuda M., Torgerson T.R., Selmi C., Gambineri E., Carneiro-Sampaio M., Mannurita S.C., et al. The spectrum of autoantibodies in IPEX syndrome is broad and includes anti-mitochondrial autoantibodies. Journal of autoimmunity 2010, 35:265-268.
58. Yong P.L., Russo P., Sullivan K.E. Use of sirolimus in IPEX and IPEX-like children. Journal of clinical immunology 2008, 28:581-587.
59. Zhan H., Sinclair J., Adams S., Cale C.M., Murch S., Perroni L., et al. Immune reconstitution and recovery of FOXP3 (forkhead box P3)-expressing T cells after transplantation for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome. Pediatrics 2008, 121:e998-1002.
60. Barzaghi F., Passerini L., Bacchetta R. Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Frontiers in immunology 2012, 3:211.
61. Passerini L., Di Nunzio S., Gregori S., Gambineri E., Cecconi M., Seidel M.G., et al. Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. Eur J Immunol 2011, 41:1120-1131.
62. Chang X., Gao J.X., Jiang Q., Wen J., Seifers N., Su L., et al. The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. J Exp Med 2005, 202:1141-1151.
63. Chang X., Zheng P., Liu Y. Homeostatic proliferation in mice with germline FoxP3 mutation and its contribution to fatal autoimmunity. Journal of Immunology 2008, 181:2399-2406.
64. Birzele F., Fauti T., Stahl H., Lenter M.C., Simon E., Knebel D., et al. Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human. Nucleic acids research 2011.
65. Marson A., Kretschmer K., Frampton G.M., Jacobsen E.S., Polansky J.K., MacIsaac K.D., et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007, 445:931-935.
66. Sadlon T.J., Wilkinson B.G., Pederson S., Brown C.Y., Bresatz S., Gargett T., et al. Genome-wide identification of human FOXP3 target genes in natural regulatory T cells. J Immunol 2010, 185:1071-1081.
67. Zheng Y., Josefowicz S.Z., Kas A., Chu T.T., Gavin M.A., Rudensky A.Y. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007, 445:936-940.
68. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
69. Pan F., Yu H., Dang E.V., Barbi J., Pan X., Grosso J.F., et al. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science 2009, 325:1142-1146.
70. Samstein R.M., Arvey A., Josefowicz S.Z., Peng X., Reynolds A., Sandstrom R., et al. Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification. Cell 2012, 151:153-166.
71. Gavin M.A., Rasmussen J.P., Fontenot J.D., Vasta V., Manganiello V.C., Beavo J.A., et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007, 445:771-775.
72. Lin W., Haribhai D., Relland L.M., Truong N., Carlson M.R., Williams C.B., et al. Regulatory T cell development in the absence of functional Foxp3. Nat Immunol 2007, 8:359-368.
73. Li B., Samanta A., Song X., Iacono K.T., Bembas K., Tao R., et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:4571-4576.
74. Blochl H., Schmitz R., Schroder U. Human-alpha-interferon on xenotransplanted human colonic adenocarcinomas in nude mice. Strahlenther Onkol 1989, 165:548-549.
75. Miller F.W., Alfredsson L., Costenbader K.H., Kamen D.L., Nelson L.M., Norris J.M., et al. Epidemiology of environmental exposures and human autoimmune diseases: Findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. Journal of autoimmunity 2012, 39:259-271.
76. Miller F.W., Pollard K.M., Parks C.G., Germolec D.R., Leung P.S., Selmi C., et al. Criteria for environmentally associated autoimmune diseases. Journal of autoimmunity 2012, 39:253-258.
77. Ngalamika O., Zhang Y., Yin H., Zhao M., Gershwin M.E., Lu Q. Epigenetics, autoimmunity and hematologic malignancies: A comprehensive review. Journal of autoimmunity 2012, 39:451-465.
78. Sanchez-Pedreno P., Garcia-Bravo B., Rodriguez-Pichardo A., Camacho F. Different clinical presentations in photosensitivity to musk ambrette. Photodermatol 1989, 6:103-105.
79. Selmi C., Leung P.S., Sherr D.H., Diaz M., Nyland J.F., Monestier M., et al. Mechanisms of environmental influence on human autoimmunity: A national institute of environmental health sciences expert panel workshop. Journal of autoimmunity 2012, 39:272-284.
80. Selmi C., Lu Q., Humble M.C. Heritability versus the role of the environment in autoimmunity. Journal of autoimmunity 2012, 39:249-252.
81. De Santis M., Selmi C. The therapeutic potential of epigenetics in autoimmune diseases. Clin Rev Allergy Immunol 2012, 42:92-101.
82. Lin H.S., Hu C.Y., Chan H.Y., Liew Y.Y., Huang H.P., Lepescheux L., et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. British journal of pharmacology 2007, 150:862-872.
83. Zhou X., Hua X., Ding X., Bian Y., Wang X. Trichostatin differentially regulates Th1 and Th2 responses and alleviates rheumatoid arthritis in mice. Journal of clinical immunology 2011, 31:395-405.
84. Reilly C.M., Thomas M., Gogal R., Olgun S., Santo A., Sodhi R., et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. Journal of autoimmunity 2008, 31:123-130.
85. Camelo S., Iglesias A.H., Hwang D., Due B., Ryu H., Smith K., et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. Journal of neuroimmunology 2005, 164:10-21.
86. Saouaf S.J., Li B., Zhang G., Shen Y., Furuuchi N., Hancock W.W., et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Experimental and molecular pathology 2009, 87:99-104.
87. Dowdell K.C., Pesnicak L., Hoffmann V., Steadman K., Remaley A.T., Cohen J.I., et al. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS). Experimental hematology 2009, 37:487-494.
88. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007, 13:1299-1307.
89. Brooks W.H., Le Dantec C., Pers J.O., Youinou P., Renaudineau Y. Epigenetics and autoimmunity. Journal of autoimmunity 2010, 34:J207-J219.
90. Vojinovic J., Damjanov N., D'Urzo C., Furlan A., Susic G., Pasic S., et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2011, 63:1452-1458.
91. Holmes D., Gao J., Su L. Foxp3 inhibits HDAC1 activity to modulate gene expression in human T cells. Virology 2011, 421:12-18.